SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽Demo🎬Demo VideoℹVision

What mechanisms cause cholinergic dysfunction in early AD/MCI without neuronal loss?

OPEN

The abstract reveals that MCI and early AD patients show cholinergic dysfunction without actual neurodegeneration, contrasting with advanced AD. The specific molecular mechanisms underlying this functional decline preceding cell death are not explained, yet understanding this could enable earlier therapeutic intervention. Gap type: unexplained_observation Source paper: The cholinergic system in aging and neuronal degeneration. (2011, Behavioural brain research, PMID:21145918)

Priority: 0.85 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: What mechanisms cause cholinergic dysfunction in early AD/MCI without neuronal loss? is a 0.85 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What mechanisms cause cholinergic dysfunction in early AD/MCI without neuronal loss? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (21)

entities-ros→ADentities-atp7b-gene→ADentities-histone-methylation→ADTAU→ADTDP-43→AD
▸ Show 16 more

biomarker for (1)

tau cleavage products→AD

causes (6)

AD→neurodegenerationPHOSPHORYLATED_TAU→ADBETA_AMYLOID→ADAD→IMMUNE_TOLAD→memory_loss
▸ Show 1 more

contributes to (1)

NEUROINFLAMMATION→AD

cross disease mechanism in (5)

MAPT→ADTREM2→ADNLRP3→ADPINK1→ADGRN→AD

depleted in (1)

SPM_levels→AD

prevents (1)

NAD+ augmentation→AD

protective against (1)

cognitive stimulation→AD

regulates (1)

AD→PROTEOME

risk factor for (4)

genetically at-risk individuals→ADAPOE ε4→ADmicroglial priming→ADAPOE4→AD

targets (1)

resveratrol→AD

therapeutic target for (6)

TREM2→ADCCR2→ADSaracatinib→ADanti-amyloid antibodies→ADNAD+ augmentation→AD
▸ Show 1 more

treats (1)

HTL9936→AD
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps